Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belagenpumatucel-L

Next Previous
Drug Profile

Belagenpumatucel-L

Alternative Names: Glionix; Lucanix; Ranagengliotucel-T; TGF-beta2 antisense gene modified allogeneic tumour cell vaccine - NovaRx

Latest Information Update: 19 Aug 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Developer NovaRx Corporation
  • Class Antisense DNA; Cancer vaccines; DNA vaccines; Tumour cell vaccines
  • Mechanism of Action Immunostimulants; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioma; Non-small cell lung cancer

Most Recent Events

  • 19 Aug 2016 NovaRx intends to initiate new clinical studies for Belagenpumatucel-L, either as monotherapy or combination therapy
  • 28 Sep 2013 Efficacy data from a phase III trial in Non-small cell lung cancer presented at the European Cancer Congress 2013 (ECC-2013)
  • 25 Jul 2013 Discontinued - Phase-I for Glioma in USA (SC) prior to July 2013
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top